Allarity Therapeutics
Yahoo Finance • last year
Allarity Therapeutics to Present at Biomarkers Europe 2023
Allarity will present on development of several drug-specific DRP® companiondiagnostics, and participate in a panel discussion with speakers from Merck and Roche BOSTON, October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Compa... Full story
Yahoo Finance • last year
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients BOSTON (August 30, 2023)... Full story
Yahoo Finance • last year
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for... Full story
Yahoo Finance • last year
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for... Full story
Yahoo Finance • last year
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 29, 2023 Press Release BOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical comp... Full story
Yahoo Finance • last year
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion... Full story
Yahoo Finance • last year
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel... Full story
Yahoo Finance • 2 years ago
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP® Companion Diagnost... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipatedinH2 2023. Press release BOSTON — March 28, 2023– Allarity Therapeutics, Inc. (NASDAQ... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
Company anticipates that the combination of pan-TKI dovitinib and PARP inhibitor stenoparib maygenerate synergistic anti-cancer activity Program initiation marks key milestone in Allarity’s clinical strategy shift towards combination the... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diag... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diag... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion d... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
Cambridge, MA U.S.A. (October 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Press release Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DR... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics (NASDAQ: ALLR): Diamond in the Rough
NY City, New York, United States, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diamond in the Rough Click here for full length version of article. Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical stage oncology therapeutics company founde... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
New strategy aligns with ongoing shift in oncology standard-of-care towards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial prospects Newpipeline strategy follows Type C m... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press Release Cambridge, MA, U.S.A.(July11,2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company d... Full story
